Laura Quan Man Chow, MD, FRCPC

home / authors / laura-quan-man-chow-md-frcpc

Articles

Rationale for Evaluating Ceritinib in ALK-Positive Patients With NSCLC

Rationale for Evaluating Ceritinib in ALK-Positive Patients With NSCLC

November 5th 2019

Laura Quan Man Chow, MD, FRCPC, discusses the rationale for evaluating ceritinib in patients with&nbsp;<em>ALK</em>-positive non&ndash;small cell lung cancer in the ASCEND-7 trial.